115 56

Cited 0 times in

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials

Authors
 Alexander Drilon  ;  Salvatore Siena  ;  Rafal Dziadziuszko  ;  Fabrice Barlesi  ;  Matthew G Krebs  ;  Alice T Shaw  ;  Filippo de Braud  ;  Christian Rolfo  ;  Myung-Ju Ahn  ;  Jürgen Wolf  ;  Takashi Seto  ;  Byoung Chul Cho  ;  Manish R Patel  ;  Chao-Hua Chiu  ;  Thomas John  ;  Koichi Goto  ;  Christos S Karapetis  ;  Hendrick-Tobias Arkenau  ;  Sang-We Kim  ;  Yuichiro Ohe  ;  Yu-Chung Li  ;  Young K Chae  ;  Christine H Chung  ;  Gregory A Otterson  ;  Haruyasu Murakami  ;  Chia-Chi Lin  ;  Daniel S W Tan  ;  Hans Prenen  ;  Todd Riehl  ;  Edna Chow-Maneval  ;  Brian Simmons  ;  Na Cui  ;  Ann Johnson  ;  Susan Eng  ;  Timothy R Wilson  ;  Robert C Doebele 
Citation
 LANCET ONCOLOGY, Vol.21(2) : 261-270, 2020-02 
Journal Title
LANCET ONCOLOGY
ISSN
 1470-2045 
Issue Date
2020-02
MeSH
Antineoplastic Agents / adverse effects ; Antineoplastic Agents / therapeutic use* ; Benzamides / adverse effects ; Benzamides / therapeutic use* ; Biomarkers, Tumor / antagonists & inhibitors* ; Biomarkers, Tumor / genetics* ; Carcinoma, Non-Small-Cell Lung / drug therapy* ; Carcinoma, Non-Small-Cell Lung / genetics ; Carcinoma, Non-Small-Cell Lung / mortality ; Carcinoma, Non-Small-Cell Lung / secondary ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Female ; Gene Fusion* ; Humans ; Indazoles / adverse effects ; Indazoles / therapeutic use* ; Lung Neoplasms / drug therapy* ; Lung Neoplasms / genetics ; Lung Neoplasms / mortality ; Lung Neoplasms / pathology ; Male ; Middle Aged ; Multicenter Studies as Topic ; Progression-Free Survival ; Protein Kinase Inhibitors / adverse effects ; Protein Kinase Inhibitors / therapeutic use* ; Protein-Tyrosine Kinases / antagonists & inhibitors* ; Protein-Tyrosine Kinases / genetics* ; Proto-Oncogene Proteins / antagonists & inhibitors* ; Proto-Oncogene Proteins / genetics* ; Time Factors
Abstract
Background Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including nonsmall-cell lung cancer (NSCLC). Up to 36% of patients with ROS1 fusion-positive NSCLC have brain metastases at the diagnosis of advanced disease. Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the CNS. We explored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive NSCLC. Methods We did an integrated analysis of three ongoing phase 1 or 2 trials of entrectinib (ALKA-372-001, STARTRK-1, and STARTRK-2). The efficacy-evaluable population included adult patients (aged >= 18 years) with locally advanced or metastatic ROS1 fusion-positive NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at least 12 months' follow-up. All patients had an Eastern Cooperative Oncology Group performance status of 0-2, and previous cancer treatment (except for ROS1 inhibitors) was allowed. The primary endpoints were the proportion of patients with an objective response (complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1) and duration of response, and were evaluated by blinded independent central review. The safety-evaluable population for the safety analysis included all patients with ROS1 fusion-positive NSCLC in the three trials who received at least one dose of entrectinib (irrespective of dose or duration of follow-up). These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001). Findings Patients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018), 41 (77%; 95% CI 64-88) of 53 patients in the efficacy-evaluable population had an objective response. Median follow-up was 15.5 months (IQR 13.4-20.2). Median duration of response was 24.6 months (95% CI 11.4-34.8). In the safety-evaluable population, 79 (59%) of 134 patients had grade 1 or 2 treatment-related adverse events. 46 (34%) of 134 patients had grade 3 or 4 treatment-related adverse events, with the most common being weight increase (ten [8%]) and neutropenia (five [4%]). 15 (11%) patients had serious treatmentrelated adverse events, the most common of which were nervous system disorders (four [3%]) and cardiac disorders (three [2%]). No treatment-related deaths occurred. Interpretation Entrectinib is active with durable disease control in patients with ROS1 fusion-positive NSCLC, and is well tolerated with a manageable safety profile, snaking it amenable to long-term dosing in these patients. These data highlight the need to routinely test for ROS1 fusions to broaden therapeutic options for patients with ROS1 fusion-positive NSCLC.
Files in This Item:
T9992020469.pdf Download
DOI
10.1016/S1470-2045(19)30690-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190244
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links